Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020087937 - COMPOSITION FOR TREATING LIVER CANCER ACCOMPANIED BY FIBROSIS

Publication Number WO/2020/087937
Publication Date 07.05.2020
International Application No. PCT/CN2019/091265
International Filing Date 14.06.2019
IPC
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/44 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • 南方医科大学中西医结合医院 INTEGRATED HOSPITAL OF TRADITIONAL CHINESE MEDICINE, SOUTHERN MEDICAL UNIVERSITY [CN]/[CN]
Inventors
  • 洪健 HONG, Jian
  • 蒋煜川 JIANG, Yuchuan
  • 陈鹏 CHEN, Peng
  • 戴冠齐 DAI, Guanqi
Agents
  • 广州嘉权专利商标事务所有限公司 JIAQUAN IP LAW FIRM
Priority Data
201811264860.029.10.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) COMPOSITION FOR TREATING LIVER CANCER ACCOMPANIED BY FIBROSIS
(FR) COMPOSITION POUR LE TRAITEMENT DU CANCER DU FOIE ACCOMPAGNÉ D'UNE FIBROSE
(ZH) 治疗伴有纤维化肝癌的组合物
Abstract
(EN)
Disclosed is a composition for treating liver cancer accompanied by fibrosis, the active ingredients thereof comprising at least one SYK inhibitor and at least one multi-target kinase inhibitor against liver cancer. The inventor discovered, by means of experimentation, that by combined application of an SYK inhibitor targeting the liver micro-environment and the multi-target kinase inhibitor Sorafenib or Reforafenib against liver cancer, the SYK inhibitor enhances the cancer-inhibiting effect of Sorafenib or Reforafenib, and further extends the survival period of model mice, thus demonstrating that the combined application of SYK inhibitors and multi-target kinase inhibitors against liver cancer has a good therapeutic effect on liver cancer accompanied by fibrosis.
(FR)
L'invention concerne une composition pour le traitement du cancer du foie accompagné d'une fibrose, dont les principes actifs comprennent au moins un inhibiteur de SYK et au moins un inhibiteur de kinase multi-cible contre le cancer du foie. L'inventeur a découvert, au moyen d'une expérimentation, qu'en appliquant de manière combinée un inhibiteur de SYK ciblant le micro-environnement du foie et l'inhibiteur de kinase multi-cible Sorafenib ou Reforafenib contre le cancer du foie, l'inhibiteur de SYK améliore l'effet d'inhibition du cancer du Sorafenib ou Reforafenib et prolonge en outre la période de survie de modèles murins, démontrant ainsi que l'application combinée d'inhibiteurs de SYK et d'inhibiteurs de kinases multi-cibles contre le cancer du foie possède un bon effet thérapeutique sur le cancer du foie accompagné d'une fibrose.
(ZH)
本发明公开了一种治疗伴有纤维化肝癌的组合物,其活性成分包括至少一种SYK抑制剂和至少一种针对肝癌的多靶点激酶抑制剂。发明人通过实验发现,联合应用针对肝脏微环境的SYK抑制剂和针对肝癌的多靶点激酶抑制剂Sorafenib或Reforafenib,SYK抑制剂增强了Sorafenib或Reforafenib的抑癌作用,并进一步延长了模型小鼠的生存期,说明SYK抑制剂和针对肝癌的多靶点激酶抑制剂联合应用对伴有纤维化肝癌具有很好的治疗作用。
Also published as
Latest bibliographic data on file with the International Bureau